Tirzepatide is a 39-amino-acid synthetic peptide developed by Eli Lilly. It does something most older injectables don't: it activates two receptors at once, the receptor for GIP (glucose-dependent insulinotropic polypeptide) and the receptor for GLP-1 (glucagon-like peptide-1). Both are gut hormones that help control blood sugar, insulin release, and appetite. That dual action is why it gets described as a "twincretin."
You'll see it sold under two brand names. Mounjaro is the version approved for type 2 diabetes. Zepbound is the same molecule approved for weight management and, more recently, obstructive sleep apnea.
What it is and how it works
The peptide is built on the GIP backbone, with substitutions that give it activity at the GLP-1 receptor too. A C20 fatty-diacid chain is attached to one of the lysine residues. That fatty chain binds reversibly to albumin in the blood, which slows clearance and protects the peptide from the enzyme (DPP-4) that normally chews up these hormones. The practical result is an elimination half-life of around five days, long enough for once-weekly injection (DrugBank).
Interestingly, the two receptors aren't engaged equally. Pharmacology work has described tirzepatide as an imbalanced and biased agonist: it mimics native GIP closely at the GIP receptor, but at the GLP-1 receptor it skews signaling toward cAMP production over β-arrestin recruitment (Willard et al., 2020, JCI Insight). The downstream effects show up as better glucose-dependent insulin secretion, improved insulin sensitivity, reduced appetite, and changes in how the body handles fat.
What the trials found
This is a heavily studied drug, with two large phase 3 programs.
The SURPASS trials looked at type 2 diabetes. Across SURPASS-1 through -5, tirzepatide at 5, 10, and 15 mg lowered HbA1c by roughly 1.9 to 2.6 percentage points, with body-weight reductions of about 6.6% to 13.9% depending on dose and study. One head-to-head trial, SURPASS-2, compared it against semaglutide and reported superior glycemic control.
The SURMOUNT program looked at obesity. In SURMOUNT-1, a 72-week trial in adults with obesity or overweight, mean weight loss was 16.0% on 5 mg, 21.4% on 10 mg, and 22.5% on 15 mg, against 2.4% for placebo (Jastreboff et al., 2022, NEJM). For sleep apnea, the SURMOUNT-OSA trials measured the apnea-hypopnea index and found large reductions versus placebo, which supported the third approval.
Regulatory status
- Type 2 diabetes (Mounjaro): FDA approved May 2022
- Chronic weight management (Zepbound): FDA approved November 2023
- Moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound): FDA approved December 2024, the first drug ever approved for OSA
This is a prescription medication. None of the above is medical or dosing advice, and dosing decisions belong with a clinician.
The quality and sourcing angle
Because demand outran supply, a large gray market grew up around tirzepatide sold outside the licensed channel, including "compounded" versions and material marketed as research chemicals. The regulatory picture has tightened. The FDA declared the tirzepatide shortage resolved in October 2024 and ended enforcement discretion for compounding in early 2025; tirzepatide was never added to the 503B bulk-compounding list, and the agency has issued warning letters over illegally produced material (Partnership for Safe Medicines).
For anyone evaluating non-pharmacy product, the FDA has flagged real problems with unapproved GLP-1 and dual-agonist drugs: uncertain identity and purity, dosing errors with multidose vials, and counterfeit supply (FDA: Concerns with Unapproved GLP-1 Drugs). Material sold "for research use only / not for human consumption" is exactly that, and it carries no guarantee that what's in the vial matches the label. A current third-party certificate of analysis confirming identity and purity is the minimum any buyer should expect to see, and it doesn't substitute for the safety record of an approved, pharmacy-dispensed product.
peptideone.org aggregates public information and does not sell peptides, test products, or give medical advice.